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Abstract
Background: Although the prognosis of core- binding factor (CBF) acute myeloid 
leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse 
and may require allogeneic hematopoietic cell transplantation (alloHCT). However, 
there is no validated widely accepted scoring system to predict patient subsets with 
higher risk of relapse.
Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21)
(q22;q22).
Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 
27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease- 
free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, 
KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild 
type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared 
with hyper- or hypodiploidy were included in a scoring system (named I- CBFit). 
DFS rate at 2 years was 76% for patients with a low- risk I- CBFit score compared with 
36% for those with a high- risk I- CBFit score (P < 0.0001). Low- vs high- risk OS at 
2 years was 89% vs 51% (P < 0.0001).
Conclusions: I- CBFit composed of readily available risk factors can be useful to 
tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, 
patients with a low- risk I- CBFit score).
K E Y W O R D S
acute myeloid leukemia, core-binding factor, disease-free survival, KIT mutation, predictive value, 
relapse, scoring system
1 |  INTRODUCTION
Acute myeloid leukemia (AML) with rearrangements involving 
genes encoding subunits of core- binding factor (CBF), a group of 
DNA- binding transcription factor complexes composed of α and 
β subunits, shares similar pathogenesis and clinical features and 
is considered as a distinct subset in AML.1-4 Translocation(8;21)
(q22;q22) and inv(16)(p13q22), the most frequent cytogenetic 
abnormalities occurring in CBF- AML, lead to the creation of 
the fusion genes RUNX1/RUNXT1 and CBFB/MYH11 that dis-
rupt, respectively, the α and β subunits of CBF, dysregulate he-
matopoiesis, and thus contribute to leukemogenesis.5
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Although the prognosis of CBF- AML is better than other 
subtypes of AML, approximately 30%- 40% of the patients 
still relapse and may require allogeneic hematopoietic cell 
transplantation (HCT).6-8 A scoring system to predict who 
has a higher risk of relapse at the time of diagnosis may be 
clinically valuable to guide decision- making. There have been 
only a few studies attempting to develop a scoring system for 
poor outcomes of CBF- AML (eg, relapse and disease- free 
survival [DFS]).6,8 The relative rarity of CBF- AML (approx-
imately 15%- 20% of AML cases) in adults9 and its relatively 
good prognosis may have limited these efforts. A useful 
prognostic system requires a large sample size and long fol-
low- up time including all treatment data. This is challenging, 
even for large registries or cooperative groups. For example, 
the Center for International Blood and Marrow Transplant 
Research (CIBMTR) only has data of patients with CBF- 
AML receiving a HCT, while US cooperative groups may 
have too few patients with a long follow- up to examine out-
comes after HCT. Moreover, recent studies clearly indicate 
that AMLs with t(8;21) (q22;q22) and AMLs with inv(16) 
(p13q22) are two different diseases regarding patient and 
disease characteristics.2,6,8,10-14 Each cytogenetic subgroup 
therefore should be evaluated separately to develop a specific 
prognostic scoring system.
In this multicenter study, we created an extensive database 
including US and European centers for CBF- AML patients 
with t(8;21) (q22;q22), and developed and validated a signif-
icant risk scoring system with high predictive probabilities.
2 |  METHODS
Eleven centers in the US and Europe collaborated to collect 
data on 550 CBF- AML patients. Two- hundred and forty- 
seven of these patients had t(8;21)(q22;q22) and are the 
subject of this report. Inclusion criteria were as follows: (a) 
AML patients with t(8;21)(q22;q22) or RUNX1-RUNX1T1 
confirmed by the reporting institutions; (b) cases diagnosed 
between July 1996 and January 2017. Data were uniformly 
collected by completing a predesigned data spreadsheet. The 
data form included the following: patient characteristics (age, 
sex, race); disease characteristics (date of diagnosis, white 
blood cell count [WBC] at diagnosis [×109/L], cytogenetics, 
KIT D816V mutational status, primary or secondary AML); 
therapy characteristics (induction regimens and their num-
ber, consolidation regimens, and number of cycles); HCT 
(autologous or allogeneic, donor type, remission status at 
HCT); and events (relapse, death, or alive at last contact). 
Patients’ data were anonymously transferred to University of 
Minnesota where the main database was created and man-
aged. This study was approved by the Institutional Review 
Board Human Subjects Committee at the University of 
Minnesota.
2.1 | Definitions
Secondary AML was assigned if a patient had a history of 
chemotherapy/radiation therapy for a malignancy and/or 
had a history of preleukemic disease (eg, myelodysplastic 
syndrome [MDS], myeloproliferative neoplasm [MPN]). In 
cytogenetic evaluation, a total number of 46 chromosomes 
were defined as pseudodiploidy in one clone or each clone 
(given this patients had translocation, it was not named dip-
loidy), and if chromosome number was higher or lower than 
46 chromosomes in any clone, it was defined, respectively, as 
hyperdiploidy and hypodiploidy.
2.2 | Statistical analysis
The sample of 247 patients was described using the median 
and range for continuous variables, and frequency and per-
centage for categorical variables.
The binary outcome was defined as death or relapse within 
2 years of diagnosis. A total of 89 patients experienced death 
or relapse within 2 years, while 158 patients survived with-
out relapse or were censored at the last contact alive (or in 
remission).
A set of potential predictors for our outcome of relapse- 
free survival was selected to build the risk score model, which 
were used to predict the probability of death or relapse in 
2 years. The predictors included age, sex, race (Caucasian), 
WBC at diagnosis, - X, - Y, chromosome 5 or 7 abnormalities, 
chromosome 4 abnormalities, chromosome 9 abnormalities, 
trisomy 8, number of chromosomes, KIT D816V mutation, 
and primary AML. The missing values for the variable KIT 
D816V mutation were combined into the category nontested 
instead of imputing the variable, so as to allow risk prediction 
when this variable is missing. The remaining covariates that 
had missing values in the dataset were variables considered 
unlikely to be missing in clinical practice, and thus, multiple 
imputation was used so as to construct a clinically meaningful 
risk score that made full use of available patient information.
Full details of the statistical analysis are provided in the 
Appendix S1. In brief, forward stepwise logistic regression 
was used, with the binary outcome of two- year relapse or 
death and the predictors discussed above. The optimal thresh-
old for binary predictions was chosen to maximize equally 
the sensitivity and specificity. A validation study was used 
to assess the performance of the risk score model using five-
fold cross- validation to estimate specificity, sensitivity, accu-
racy, positive predictive value (PPV), and negative predictive 
value (NPV).
We performed three sensitivity analyses. In the first, 
patients were censored upon allogeneic HCT (alloHCT) at 
CR1, as this is not a standard therapy. In the second, we con-
sidered only survival (rather than disease- free survival). In 
the final sensitivity analysis, we imputed all missing values 
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(including KIT D816V mutation) to create a risk score that 
would require all relevant covariates to be observed rather 
than allowing for the possibility that some are unavailable to 
the clinician.
3 |  RESULTS
The characteristics of the test and validation groups combined 
are provided in Table 1. Patients were mostly male, were 
Caucasian, and had a median age of 47 years, and 17.4% had 
secondary AML. Additional cytogenetic abnormalities were 
frequently observed (58.7%), and 44.5% of patients had a hy-
podiploid or hyperdiploid clone. KIT D816V mutation was 
present in 11.3% of patients (17.8% of the patients tested), 
and any KIT mutations were detected in 16.6% of patients 
(25.7% of the patients tested). There was no association be-
tween KIT mutation (positive, negative, nontested) and WBC 
(Figure S1).
Complete remission (CR) was achieved in the vast ma-
jority of patients (92.7) (Table 1). Relapse occurred in 
67 patients (27.1%) at a median of 10.6 months (range 
1- 65.5 months). AlloHCT was performed in 61 patients 
(24.7%): 31 with CR1 (12.5%), 19 with ≥CR2 (7.6%), and 10 
(4.0%) with active leukemia (all relapsed after CR). AlloHCT 
in CR1 was performed at a median of 6 months (range 2 to 
13.1 months) from diagnosis and 4 months (1.1- 12 months) 
from the date of CR1. The median follow- up was 64 months 
(0.5 to 1378 months).
The risk factors and risk ratios from a logistic regression 
model are presented in Table 2. Older age, higher WBC at di-
agnosis, KIT D816V mutation, and a pseudodiploid karyotype 
were associated with higher risks of death or disease relapse. 
Race, sex, and primary vs. secondary AML had no impact.
The risk of death or relapse within 2 years associated with 
the covariates retained in the predictive risk score is shown 
in Table 2. The concordance statistic (a measure of the model 
fit, also called the area under curve (AUC), or area under the 
receiver operating characteristics (ROC) curve for the predic-
tions) is 0.756 (Figure S2). The optimal risk score is found by 
computing the following linear score:
The full set of results of the validation study along with 
the sensitivity analysis results (the highest of the conditional 
probabilities was negative predictive value [NPV], 80%) are 
presented in Table S1. When I- CBFit > 0, a patient is classed 
as being at high risk of death or relapse within 2 years. DFS 
rate at 2 years was 76% for patients with a low- risk I- CBFit 
score compared with 36% for those with a high- risk I- CBFit 
score (P < 0.0001). Low- vs high- risk OS at 2 years was 89% 
vs 51%, P < 0.0001 (Figures 1 and 2).
DFS at 2 years was 80% for patients with I- CBFit low risk 
not undergoing alloHCT in CR1, was 82% for patients with 
I- CBFit low risk undergoing alloHCT in CR1, was 33% for 
patients with I- CBFit high risk not undergoing alloHCT in 
CR1, and was 67% for patients with I- CBFit high risk un-
dergoing alloHCT in CR1, P = <0.0001 (Figure 3). OS at 
2 years was 91% for patients with I- CBFit low risk regard-
less of alloHCT in CR1, was 52% for patients with I- CBFit 
high risk not undergoing alloHCT in CR1, and was 73% for 
patients with I- CBFit high risk undergoing alloHCT in CR1, 
P < 0.0001 (Figure 4).
4 |  DISCUSSION
In this large study with a long follow- up, we were able to 
create and validate the risk scoring system we are calling 
the “International CBF group index for t(8;21)” (I-CBFit) in 
t(8;21) AML. We show that older age, higher WBC at di-
agnosis, and KIT D816V mutation were risk factors associ-
ated with treatment failure (relapse or death). In addition, we 
found that pseudodiploidy was also a risk factor in t(8;21), 
a novel finding. I- CBFit had a high NPV (80%) and a mod-
est specificity and accuracy for DFS, and the NPV was even 
higher for the prediction of OS.
Current treatment guidelines for CBF- AML with t(8;21) 
do not recognize heterogeneity in these patients, and thus, 
all t(8;21) AML patients generally receive the same induc-
tion and consolidation treatments. This might be appropriate 
for patients with a low- risk score who are predicted to have 
nearly an 80% chance of extended DFS. On the other hand, 
high- risk score patients may benefit from more intensive ap-
proaches in CR1. Current guidelines do not identify patients 
needing alloHCT in CR1. This new model may clarify this 
uncertainty, especially identifying patients who do not re-
quire intensive consolidations (eg, alloHCT) in CR1 given its 
high NPV. Although patients receiving alloHCT in CR1 was 
limited, when we analyzed the impact of alloHCT it seemed 
that patients with an I- CBFit low- risk score had similar DFS 
and OS regardless of alloHCT.
KIT mutations have been reported in 15%- 46% of adults 
patients with t(8;21) CBF- AML.13,15-18 KIT D816V muta-
tions were reported in 4%- 28% and strongly associated with 
poorer DFS (6%- 48%).13,16,19,20 In pediatric populations, KIT 
mutations clustered in exon 17 and exon 8 were identified 
in 20- 30% of the CBF- AML patients,21-23 yet its effect on 
I-CBFIT Score=−3.05
+0.03Age years
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prognosis is not agreed upon.22,24 A meta- analysis indicated 
KIT mutation increased relapse risk (RR at 2 years 1.76 [95% 
CI: 1.45- 2.12]) and decreased OS 1.35 (95% CI: 1.09- 1.66).25
Chromosomal abnormalities secondary to t(8;21), mostly 
involving loss of a sex chromosome, - Y in men and - X in 
women, trisomy 8, and deletion of the long arm of chro-
mosome 9 [del(9p)] are frequently reported.6,8,14,18 In our 
T A B L E  1  Characteristics of patients
Variable Total
Number 247
Age, median (range) y 47.0 (2.0- 81.0)








Missing, n (%) 23 (9.3%)
Year of diagnosis, median (range) 2009 (1995- 2017)
Missing, n (%) 2 (0.8%)
WBC at diagnosis, median (range) ×109/L 11.7 (1.3- 139.9)




Missing, n (%) 10 (4.0%)
Cytogenetics
- X, n (%)
No 206 (83.4%)
Yes 33 (13.4%)
Missing, n (%) 8 (3.2%)
- Y, n (%)
No 192 (77.7%)
Yes 48 (19.4%)
Missing, n (%) 7 (2.8%)
Chromosome 9 abnormalities, n (%)
No 210 (85.0%)
Yes 29 (11.7%)
Missing, n (%) 8 (3.2%)
Chromosome 4 abnormalities, n (%)
No 232 (94.0%)
Yes 7 (2.8%)
Missing, n (%) 8 (3.2%)
Chromosome 5 or 7 abnormalities, n (%)
No 210 (85.0%)
Yes 28 (11.3%)




Missing, n (%) 8 (3.2%)
(Continues)
Variable Total




Missing, n (%) 8 (3.2%)
Additional cytogenetic abnormality, n (%)
Yes 145 (58.7%)
No 95 (38.5%)
Missing, n (%) 7 (2.8%)
KIT mutation, n (%)
Negative 118 (47.8%)
Positive 41 (16.6%)
Nontested/Missing, n (%) 88 (35.6%)








Missing, n (%) 1 (0.4%)
Does not apply (%) 18 (7.3%)
AlloHCT, n (%)
Yes 61 (24.7%)
Disease status at alloHCT n (%)





Does not apply 186 (75.3%)
DFS, median (range) mo 20.8 (0- 225.8)
Missing, n (%) 1 (0.4%)
OS, median (range) months 31.2 (1- 245.8)
Missing, n (%) 0 (0.0%)
AlloHCT, allogeneic hematopoietic cell transplantation; CR, complete remission; 
DFS, disease- free survival; OS, overall survival; WBC, white blood cell count.
T A B L E  1  (Continued)
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patients, additional cytogenetic abnormalities were com-
mon, as in other reports.14,18,26 Sex chromosome loss was 
reported as favorable for two- year event- free survival (66.9% 
vs 43.0%, P = 0.031).18 In contrast, DFS was shorter for male 
patients with loss of the Y chromosome. In another study,8 
loss of a sex chromosome was associated with increased CR 
rates in CBF- AML.14 We found no particular chromosomal 
abnormality to be associated with poor outcome. However, 
consistent with findings of Krauth et al18 loss of a sex chro-
mosome had a modestly favorable, but not significant effect 
on DFS. We also found that the chromosome number was 
important, with patients with pseudodiploid karyotypes hav-
ing worse outcome compared with those with hypodiploidy 
or hyperdiploidy.
Higher WBCs were found to be associated with poorer 
outcomes.8 Schlenk et al8 described a scoring system using 
two factors, high WBC, and low platelet counts, to be prog-
nostic. Low platelet count was also a poor prognostic factor 
in a CALGB/Alliance study.6 In our study, we did not find a 
correlation between KIT mutation and WBC.
An earlier CALGB/Alliance study showed that age was 
associated with shorter overall survival (OS).6 In a more re-
cent CALGB/Alliance study,27 3- year OS rate was 61% for 
adults younger than 60 years vs only 47% for those at least 
60 years old. Appelbaum et al14 showed that age is associated 
with a shorter OS.
We were able to collect data over a two- decade period 
and believe this long time period does not adversely impact 
the validity of the study as (a) the type and number of in-
duction or consolidation therapies did not have an impact on 
outcomes and (b) the most widely used treatments (7 + 3 in 
induction phase and high- dose cytarabine in consolidation 
phase) have not changed over this time. Although this is a 
retrospective study, we find the data robust and substantial 
given the lengthy time period of patient follow- up. In fact, 
long- term follow- up allowed complete evaluation in this rel-
atively good prognostic disease.
Another limitation is that molecular abnormalities, in-
cluding mutations in the KIT and FLT3 genes, were not uni-
formly tested. As a result, information on KIT mutational 
status is missing in approximately one- third of the patients. 
However, KIT mutation was associated with significantly 
decreased survival compared with KIT wild type, whereas 
outcomes of patients with the KIT mutational status un-
tested fell between outcomes of patients with KIT muta-
tions and those with wild- type KIT; this might be expected 
given that some but not all untested patients would have 
mutated KIT. This strongly supports the adverse effect of 
a KIT mutation.
T A B L E  2  Risk ratios of risk factors for death or relapse
Risk factor Risk ratio P- value
Age 1.031 0.0017
KIT D816V mutation positive 
(Ref = negative)
4.331 0.0018
KIT D816V mutation nontested/
missing (Ref = negative)
2.567 0.0036
WBC at diagnosis 1.018 0.0361
Number of chromosomes 
(Ref = nonpseudodiploidy)
2.552 0.0035
WBC indicates white blood cell count.
F I G U R E  1  Patients with a low I- CBFit score (red curve with 
95% CI) had significantly higher DFS compared with those who had a 
















Strata I-CBFit highI-CBFit low
DFS by I-CBFit (a high risk corresponds to a risk score of 0 or greater)
0 365 730 1095 1460
Time (d)
P < 0.0001
1825 2190 2555 2920 3285
F I G U R E  2  Patients with a low I- CBFit score (red curve with 
95% CI) had significantly higher OS compared with those who had a 














0 365 730 1095 1460
Time (d)
1825 2190 2555 2920 3285
OS by I-CBFit (a high risk corresponds to a risk score of 0 or greater)
Strata I-CBFit highI-CBFit low
P < 0.0001
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F I G U R E  3  DFS is stratified by 
alloHCT and I- CBFit score. AlloHCT did 
not have an impact on DFS in patients with 
a low I- CBFit score (red and green curves); 
however, patients with high I- CBFit- risk had 
improved DFS after alloHCT compared with 
































I-CBFit low without alloHCT
I-CBFit low without alloHCT
I-CBFit low with alloHCT
I-CBFit low with alloHCT
I-CBFit high with alloHCT
I-CBFit high with alloHCT
I-CBFit high without alloHCT





















F I G U R E  4  OS is stratified by 
alloHCT and I- CBFit score. AlloHCT did 
not have an impact on OS in patients with 
a low I- CBFit score (red and green curves); 
however, patients with high I- CBFit risk had 
improved OS after alloHCT compared with 





















I-CBFit low without alloHCT
I-CBFit low with alloHCT
I-CBFit high with alloHCT



























I-CBFit low without alloHCT I-CBFit low with alloHCT
I-CBFit high with alloHCTI-CBFit high without alloHCT
OS by I-CBFit and alloHCT at CR1 (a high risk corresponds to a risk score of 0 or greater)
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This new scoring system, I- CBFit, uses known and novel 
risk factors to provide a binary prediction of the risk of death 
or relapse within 2 years. Importantly, all factors and thus 
the scoring system can easily be determined at diagnosis. 
Although its validation by other studies is needed, I- CBFit 
can contribute to current treatment of patients with t(8;21) 
and tailor consolidation treatments for individual patients 
in the spirit of precision medicine to identify those who do 
not need intensified management including alloHCT during 
CR1.
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